Aligos Therapeutics Starts Phase 1 Study of ALG-170675
SOUTH SAN FRANCISCO, Calif., August 12, 2026 Aligos Therapeutics, Inc. announced that its partner Xiamen Amoytop Biotech Co., Ltd....
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., August 12, 2026 Aligos Therapeutics, Inc. announced that its partner Xiamen Amoytop Biotech Co., Ltd....
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Aligos Therapeutics has received a $25 million upfront payment from Xiamen Amoytop...
